Table 1 Demographic, clinical, and laboratory data of the chronic PIT patients studied.
Variables | Chronic PIT patients [N = 40] | |
|---|---|---|
Sex [N (%)] | Male | 17 (42.5) |
Female | 23 (57.5) | |
Age [years (mean ± SD)] | 8.14 ± 3.96 | |
Age at initial presentation [years (mean ± SD)] | 4.51 ± 2.93 | |
Duration of illness [years (mean ± SD)] | 3.67 ± 2.51 | |
Type of bleeding [N (%)] | Cutaneous | 21 (52.5) |
Mucous | 2 (5) | |
Both | 17 (42.5) | |
Severity of bleeding | ||
(IWG bleeding score) [N (%)] | Severe life threatening (4b) | 2 (5) |
Severe non-life threatening (4a) | 5 (12.5) | |
Moderate (3) | 16 (40) | |
Mild (2) | 16 (40) | |
Minor (1) | 1 (2.5) | |
Splenectomy [N (%)] | 2 (5) | |
HTN [N (%)] | 13 (32.5) | |
Initial platelet count [×109/l (mean ± SD)] | 32.67 ± 20.01 | |
Platelets at the time of sampling [× 109/l (mean ± SD)] | 124 ± 72.86 | |
Hemoglobin at the time of sampling [g/dl (mean ± SD)] | 10.98 ± 1.45 | |
TLC at the time of sampling [×109/l (mean ± SD)] | 10 ± 4.32 | |
Laboratory response [N (%)] | Complete response | 6 (15) |
Response | 6 (15) | |
No response | 28 (70) | |
Treatment received | ||
Initial treatment [N (%)] | Watchful waiting | 11 (27.5) |
Corticosteroids | 40 (100) | |
IVIg | 4 (10) | |
Platelet transfusion | 2 (5) | |
Maintenance treatment [N (%)] | Oral corticosteroids | 35 (87.5) |
Azathioprine (Imuran) | 24 (60) | |
Cyclosporine (Sandimmune) | 8 (20) | |
Mycophenolate Mofetil (Cellcept) | 1 (2.5) | |
Eltrombopag (Revolade) | 2 (5) | |